CUE ▼ -0.6% - Cue Biopharma, Inc. $CUE - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Cue Biopharma announced positive topline results from its Phase 2 study of CUE-221 in chronic spontaneous urticaria, though the stock declined 0.6% today despite the favorable clinical data. The modest pullback may reflect profit-taking following the news or investor caution pending full details on the trial's efficacy and safety metrics. 20-SEP-2026 06:00 AM ET